Pacific Biosciences Ownership
| PACB Stock | USD 1.93 0.02 1.05% |
Shares in Circulation | First Issued 2009-09-30 | Previous Quarter 272 M | Current Value 273 M | Avarage Shares Outstanding 122.7 M | Quarterly Volatility 78.1 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Pacific |
Pacific Stock Ownership Analysis
About 83.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.24. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Pacific Biosciences has Price/Earnings (P/E) ratio of 197.88. The entity recorded a loss per share of 1.46. The firm had not issued any dividends in recent years. Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California. Pacific Biosciences operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 728 people. To find out more about Pacific Biosciences of contact Christian MBA at 650 521 8000 or learn more at https://www.pacb.com.Besides selling stocks to institutional investors, Pacific Biosciences also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Pacific Biosciences' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Pacific Biosciences' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Pacific Biosciences Quarterly Liabilities And Stockholders Equity |
|
About 9.0% of Pacific Biosciences of are currently held by insiders. Unlike Pacific Biosciences' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Pacific Biosciences' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Pacific Biosciences' insider trades
Pacific Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Pacific Biosciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Pacific Biosciences of backward and forwards among themselves. Pacific Biosciences' institutional investor refers to the entity that pools money to purchase Pacific Biosciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Bank Of New York Mellon Corp | 2024-09-30 | 5.6 M | Goldman Sachs Group Inc | 2024-09-30 | 4.2 M | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 3.9 M | Capital World Investors | 2024-09-30 | 3.4 M | Northern Trust Corp | 2024-09-30 | 2.4 M | Marshall Wace Asset Management Ltd | 2024-09-30 | 2.1 M | Soros Fund Management Llc | 2024-09-30 | 2.1 M | Charles Schwab Investment Management Inc | 2024-09-30 | 2 M | Bank Of America Corp | 2024-06-30 | 1.9 M | Ark Investment Management Llc | 2024-09-30 | 33.4 M | Blackrock Inc | 2024-06-30 | 23.6 M |
Pacific Biosciences Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Pacific Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Pacific Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Pacific Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Pacific Biosciences Outstanding Bonds
Pacific Biosciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Pacific Biosciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Pacific bonds can be classified according to their maturity, which is the date when Pacific Biosciences of has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Pacific Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Pacific Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Pacific Biosciences Of Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Pacific Biosciences Of Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pacific Biosciences of. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pacific Biosciences. If investors know Pacific will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pacific Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.46) | Revenue Per Share 0.64 | Quarterly Revenue Growth (0.28) | Return On Assets (0.11) | Return On Equity (0.65) |
The market value of Pacific Biosciences is measured differently than its book value, which is the value of Pacific that is recorded on the company's balance sheet. Investors also form their own opinion of Pacific Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Pacific Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pacific Biosciences' market value can be influenced by many factors that don't directly affect Pacific Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pacific Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Pacific Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pacific Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.